Zentiva Snaps Up Alvogen’s CEE Operations
Alvogen To Focus On Asia And Alvotech’s Biosimilars
Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the generics and OTC markets.
You may also be interested in...
Zentiva has made some high-profile changes to its senior leadership team in recent weeks. Former general manager of its Czech Republic and Slovakia business Soňa Porubská is taking on a new role as global head of corporate affairs, succeeded by Boris Sananes.
Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.
Alvogen has struck a licensing deal with Yas Holding that gives the firm exclusive distribution rights to a portfolio of 28 generics in the Middle East and North Africa region from 2020.